Reported Earlier, Actuate Therapeutics Prices $22.4M Initial Public Offering Of 2.8M Common Shares At $8/Share
Reported Earlier, Actuate Therapeutics Prices $22.4M Initial Public Offering Of 2.8M Common Shares At $8/Share
Actuate Therapeutics announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the "Offering").
Actuate Therapeutics今日宣佈其普通股的首次公開發行價格爲每股8.00美元，發行量爲280萬股，發行總額爲2240萬美元，不包括承銷折扣和發行費用（"發售"）。
In addition, the Company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares representing 15% of the shares sold in this offering, solely to cover over-allotments, if any, less the underwriting discount. All of the shares are being offered by the Company.
此外，該公司已授予承銷商30天期權，購買多達42萬股額外股份，佔本次發行股份的15％，僅用於覆蓋可能的超額配售，不包括承銷折扣。這些股份全部由公司提供。
The shares are expected to begin trading on the Nasdaq Global Market tomorrow, August 13, 2024, under the symbol "ACTU." The Offering is expected to close on August 14, 2024, subject to the satisfaction of customary closing conditions.
這些股票預計將於2024年8月13日在納斯達克全球市場上以ACTU爲標的開始交易。預計發售將於2024年8月14日結束，前提是符合慣例的結算條件。
